Mumbai: Pharmaceutical firm Suven Life Sciences Tuesday said the European Patent Office (EPO) has issued three patents to its chemical entities which are used
in treating nerve disorders.
"The company gets three patents -- EP1537113, EP1704154 and EP1856132 and the said are valid until 23, and 24, 2022, respectively," Suven said in a filing to the Bombay Stock
Exchange.
The granted claims of the patents includes therapeutic agents, useful in the treatment of neurodegenerative disorders like alzheimer’s, parkinson, and schizophrenia, the filing
added.
"We are very pleased by the grant of these patents to Suven by EPO for our pipeline of molecules in central nervous system arena that are being developed for cognitive
disorders," Suven CEO Venkat Jasti said.
With these new patents, Suven has total of seven granted EPO patents on new chemical entities.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts, it added.
PTI
First Published: Monday, November 30, 2009, 14:43